Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | NPY4R | P50391 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5974111 | 0.98 | GSR (0.40) | GSRNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL5973186 | 0.96 | GSR (0.34) | GSRALDH1A1 | |
| SCHEMBL789501 | 0.96 | GSR (0.34) | GSRALDH1A1 | |
| SCHEMBL787013 | 0.96 | GSR (0.34) | GSRALDH1A1 | |
| SCHEMBL18587049 | 0.96 | GSR (0.34) | GSRALDH1A1 | |
| SCHEMBL18587048 | 0.96 | GSR (0.34) | GSRALDH1A1 | |
| SCHEMBL19911651 | 0.96 | GSR (0.34) | GSRALDH1A1 | |
| SCHEMBL789664 | 0.87 | — | — | |
| SCHEMBL789543 | 0.87 | — | — | |
| SCHEMBL18094441 | 0.84 | ALDH1A1 (0.33) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7670613-B2 | Androgen modulators | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20100048517-A1 | ANDROGEN MODULATORS | PFIZER INC | 2010-02-25 | — | — | US | disclosed |
| EP-1781598-A1 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-0957079-B1 | ETHER COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | SHOWA DENKO KK (JP) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006006065-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060009427-A1 | 4-(2-Cyano-cyclohexyloxy)-2-trifluoromethyl-benzonitrlle, a salt, or an isomer;selective androgen receptor modulators; decrease excess sebum secretions; stimulafnts of hair growth at higher rates of cosmetically acceptable hair growth in patients with alopecia; acne; skin disorders; prostate cancer | WARNER-LAMBERT COMPANY LLC | 2006-01-12 | — | — | US | disclosed |
| US-6376702-B1 | A 1-ALKENYL ETHER | SHOWA DENKO K.K. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-6204410-B1 | FOR FREE RADICAL POLYMERIZATION | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2001-03-20 | — | — | US | disclosed |
| EP-0957079-A1 | NEW ETHER COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | Showa Denko Kabushiki Kaisha (JP) | 1999-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048517-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | GSR 2232/4885NPY1R 312/4885NPY2R 194/4885 |
| US-20060009427-A1 | 4-(2-Cyano-cyclohexyloxy)-2-trifluoromethyl-benzonitrlle, a salt, or an isomer;selective androgen receptor modulators; decrease excess sebum secretions; stimulafnts of hair growth at higher rates of cosmetically acceptable hair growth in patients with alopecia; acne; skin disorders; prostate cancer | AR, FSHR, MC1R | GSR 3373/4885NPY1R 151/4885NPY2R 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.